Literature DB >> 17172872

Polo-like kinase 1: target and regulator of transcriptional control.

Bernd T Martin1, Klaus Strebhardt.   

Abstract

Deregulated cell cycle control is a hallmark of cancer cells. Developmental or other mitogenic stimuli activate the proliferation of normal cells in response to the requirements of growing tissues. In contrast, cancer cells liberate from proliferative restrictions exerted by anti-proliferative signals arising from the stroma and by endogenous genetic programs that correlate to the terminal differentiation of cells. The study of cyclin-dependent kinases (Cdks) and polo-like kinases (Plks) as evolutionary conserved regulators of the cell cycle has contributed significantly to our current understanding of the mechanisms that underlie the proliferation of mammalian cells. Given the importance of Plk1 for mitotic progression the temporal expression of Plk1 is crucial and has to be tightly regulated. It is known that steady-state Plk1 mRNA and protein levels are coordinately regulated during cell cycle progression, being low during interphase but high in mitosis. This review will summarize the current knowledge on how cell cycle-dependent transcriptional regulation of the Plk1 gene is achieved. While binding sites for various transcriptional activators are dispersed throughout the entire Plk1 promoter region, the cell cycle-dependent regulation of the Plk1 gene expression seems to be regulated by G1-specific repression rather than by G2/M-specific activation of the Plk1 transcriptional unit. The tumor suppressor gene p53 was identified as a key player in the precise restriction of Plk1 gene expression to the G2/M phase. The activity of p53 is in turn controlled by Plk1 itself indicating the existence of an auto-regulatory mechanism involved in the cell cycle-dependent regulation of the Plk1 gene. Furthermore, transcription factors regulated by Plk1 will also be subject of discussion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172872     DOI: 10.4161/cc.5.24.3538

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  29 in total

Review 1.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 3.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

4.  Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?

Authors:  Vincent Archambault; Mar Carmena
Journal:  Cell Cycle       Date:  2012-04-15       Impact factor: 4.534

5.  RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.

Authors:  Shaguna Seth; Yoshiyuki Matsui; Kathy Fosnaugh; Yan Liu; Narendra Vaish; Roger Adami; Pierrot Harvie; Rachel Johns; Gregory Severson; Tod Brown; Akihide Takagi; Susan Bell; Yan Chen; Feng Chen; Tianying Zhu; Renata Fam; Iwona Maciagiewicz; Erin Kwang; Michael McCutcheon; Ken Farber; Patrick Charmley; Michael E Houston; Alan So; Michael V Templin; Barry Polisky
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

6.  H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes.

Authors:  Theresa K Kelly; Tina Branscombe Miranda; Gangning Liang; Benjamin P Berman; Joy C Lin; Amos Tanay; Peter A Jones
Journal:  Mol Cell       Date:  2010-09-24       Impact factor: 17.970

7.  Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells.

Authors:  André Wirries; Sandra Breyer; Karl Quint; Rainer Schobert; Matthias Ocker
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

8.  RNAi screening for kinases and phosphatases identifies FoxO regulators.

Authors:  Jaakko Mattila; Jukka Kallijärvi; Oscar Puig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

9.  Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass.

Authors:  Gina Chun; Dongsoon Bae; Kristen Nickens; Travis J O'Brien; Steven R Patierno; Susan Ceryak
Journal:  Carcinogenesis       Date:  2010-01-20       Impact factor: 4.944

10.  Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.

Authors:  Travis L Schmit; Weixiong Zhong; Minakshi Nihal; Nihal Ahmad
Journal:  Cell Cycle       Date:  2009-09-02       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.